Tanguy Y. Seiwert

Also affiliated with Johns Hopkins Medicine, Johns Hopkins Bayview Medical Center, Sidney Kimmel Cancer Center, Johns Hopkins Hospital, Sidney Kimmel Comprehensive Cancer Center, University of Baltimore

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

2in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Data from A Randomized Multi-institutional Phase II Trial of Everolimus as Adjuvant Therapy in Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck

(2023)10.1158/1078-0432.c.6532910.v1

Top 100%

0DataRank

Top 100%0 citations

D. Neil Hayes, Theodore Karrison, Olivier Harismendy, José M. Flores, Tara Moore‐Medlin +17 more

Papers

Driven by 13 papers — median percentile 0. Top paper: “Persistent mutation burden drives sustained anti-tumor immune responses”.

Persistent mutation burden drives sustained anti-tumor immune responses

Nature Medicine(2023)10.1038/s41591-022-02163-w

N/A

0.747DataRank · unranked

144 citations

Archana Balan, Christopher Cherry, Karlijn Hummelink, Kim Monkhorst, Xiaoshan M. Shao +16 more

Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy

Journal for ImmunoTherapy of Cancer(2022)10.1136/jitc-2022-004688

N/A

0.743DataRank · unranked

141 citations

Jenna VanLiere Canzoniero, Samuel Rosner, Guangfan Zhang, James R. White, Zineb Belcaid +22 more

Comparison of next generation sequencing, droplet digital PCR, and quantitative real-time PCR for the earlier detection and quantification of HPV in HPV-positive oropharyngeal cancer

Oral Oncology(2022)10.1016/j.oraloncology.2022.105805

N/A

0.626DataRank · unranked

64 citations

Gypsyamber DʼSouza, Zubair Khan, Hailey Allen, Stephanie N. Henson, Tanguy Y. Seiwert +4 more

Immune-related events in individuals with solid tumors on immunotherapy associate with Th17 and Th2 signatures

Journal of Clinical Investigation(2024)10.1172/jci176567

N/A

0.500DataRank · unranked

27 citations

Soren Charmsaz, Stephanie Alden, Madelena Brancati, Howard L. Li, Aanika Balaji +38 more

Analytical and clinical performance validation of HPV-SEQ, a novel NGS-based liquid biopsy platform for detection and quantification of human papilloma virus circulating tumor DNA

Oral Oncology(2025)10.1016/j.oraloncology.2025.107445

N/A

0.330DataRank · unranked

8 citations

Anna Starus, David H. Murray, Kirsten A. Keyser, Oliver Schauer, Simon Guellert +16 more

Data from A Randomized Multi-institutional Phase II Trial of Everolimus as Adjuvant Therapy in Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck

(2023)10.1158/1078-0432.c.6532910.v1

Top 100%

0DataRank

Top 100%0 citations

D. Neil Hayes, Theodore Karrison, Olivier Harismendy, José M. Flores, Tara Moore‐Medlin +17 more

Lower survival for surgical treatment of human papillomavirus–related oropharynx cancer at community cancer centers

JNCI Journal of the National Cancer Institute(2024)10.1093/jnci/djae220

N/A

0DataRank · unranked

5 citations

Wojciech K. Mydlarz, Leila J. Mady, Christine G. Gourin, Wayne M. Koch, Nyall R. London +5 more

Pan-tumor analysis to investigate the obesity paradox in immune checkpoint blockade

Journal for ImmunoTherapy of Cancer(2025)10.1136/jitc-2024-009734

N/A

0DataRank · unranked

18 citations

Soren Charmsaz, Howard L. Li, Hua‐Ling Tsai, Ludmila Danilova, Kabeer Munjal +29 more

Impact of comorbidities on outcomes in patients with advanced head and neck cancer undergoing immunotherapy

Head & Neck(2023)10.1002/hed.27502

N/A

0DataRank · unranked

10 citations

Dylan J. Cooper, Hosam H. Alkhatib, Aditya Suru, Angelo Blancaflor, Christopher A. Maroun +13 more

Risk and response adapted de-intensified treatment for HPV-associated oropharyngeal cancer: Optima paradigm expanded experience

Oral Oncology(2021)10.1016/j.oraloncology.2021.105566

N/A

0DataRank · unranked

31 citations

Nishant Agrawal, Alexander T. Pearson, Zhen Gooi, Elizabeth A. Blair, John Cursio +13 more

First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-4256

N/A

0DataRank · unranked

98 citations

Justin F. Gainor, Margaret K. Callahan, Gerald S. Falchook, Russell K. Pachynski, Patricia LoRusso +29 more

Dose and volume de-escalation for HPV-associated oropharyngeal cancer: Long-term follow-up of the OPTIMA trial.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.6575

N/A

0DataRank · unranked

2 citations

Nishant Agrawal, Alexander T. Pearson, Tanguy Y. Seiwert, Zhen Gooi, Elizabeth A. Blair +9 more

Supplementary Data from First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response

Figshare(2023)10.1158/1078-0432.22487576.v1

Top 100%

0DataRank

Top 100%0 citations

Justin F. Gainor, Margaret K. Callahan, Gerald S. Falchook, Russell K. Pachynski, Patricia LoRusso +29 more

Tanguy Y. Seiwert

Indexed papers

Top data-sharing exemplar

Papers